Rop: Ivi & Laser Friend Or Foe ?

Published 2022 - 40th Congress of the ESCRS

Reference: PO419 | Type: ESCRS 2022 - Posters | DOI: 10.82333/t80e-q969

Authors: Mahmoud Sami Abouzeid* ¹

¹Memorial Institute of Ophthalmic Research,Giza,Egypt

Purpose

IVI vs Laser in ROP management

Either with relevance to type of ROP, zones & stages

Setting

Memorial Institute of Ophthalmic Research - Giza

Pediatric Retina clinic

Methods

Monitoring Laser pros & cons

Monitoring IVI pros & cons

Results were followed up & compared with literature within 6 months

Results

RAINBOW: ranibizumab 0.2mg proved more effective than laser

Intravitreal injection is safer than laser in type 1 ROP & APROP

IVI induces less myopia than Laser

Pegatinib is significantly effective in stage 3+

Rani is considered in cases after laser failure

Bevacizumab better than laser for stage 3 zone 1 but not zone 2

Antivegf has better structural outcome than laser in Type 1 ROP before 36 weeks

Combined vitrectomy with IVI leads to rapid regression of disease in advanced stage 4 ROP with extensive neovascularization

Laser induces less myopia than cryo as well functional & structural outcome

Large spot laser thermotherapy is 40% more efficient than conventional laser

2 staged laser fewer count & smaller spot size if compared with single session

Conclusions

Combination therapy effective & safe for type 1 ROP & APROP, applied in lower GA/ BW/ long ventilation supplementary O2 especially within 2 weeks. This claims to achieve early regression, lower recurrence & larger area of retinal vascularization. IVI & Laser combined proved reduction in Rt ventricular doppler velocity

In severe ROP, IVI is favoured

In less severe ROP, laser is favored